New Launch25 Feb 2026, 07:02 pm
Zydus Lifesciences to Launch Innovative Semaglutide Injection in India, Expanding Patient Access to GLP-1 Therapy
AI Summary
Zydus Lifesciences Ltd, an innovation-led life-sciences company, plans to launch Semaglutide Injection under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™ in India upon Semaglutide patent expiry. The company has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen. This novel drug-delivery system allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence and convenience, and reducing the overall cost of therapy. The drug is intended to manage Type 2 Diabetes Mellitus and Obesity.
Key Highlights
- Zydus to launch Semaglutide Injection under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™ in India upon Semaglutide patent expiry.
- The company has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen.
- The novel drug-delivery system allows patients to select and administer varying dose strengths from a single unit, enhancing patient adherence and convenience.
- The drug is intended to manage Type 2 Diabetes Mellitus and Obesity.
- The reusable pen brings greater affordability for the patients.